The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Mukesh Kamath, tendered vide his letter dated 20 March 2026, from the position of Interim Chief Financial Officer of the Company with effect from close of business hours of 31 March 2026 to take up another role within the Biocon Group.Further, the board has approved the appointment of Kedar Narayan Upadhye, Chief Financial Officer of Biocon Biologics, as the Chief Financial Officer (Key Managerial Personnel and Senior Management Personnel) of the Company, with effect from 01 April 2026. Powered by Capital Market - Live News

The board of Biocon at its meeting held on 27 March 2026 has approved the appointment of Shreehas Pradeep Tambe (DIN: 09796480), Chief Executive Officer and Managing Director of Biocon Biologics (BBL), as an Additional Director of the Company w.e.f. 01 April 2026 and Chief Executive Officer and Managing Director (Key Managerial Personnel of the Company) for a period of 5 (five) years effective from 01 April 2026, subject to the approval of the shareholders of the Company. Powered by Capital Market - Live News

The board of Biocon at its meeting held on 27 March 2026 has accepted the resignation of Siddharth Mittal (DIN: 03230757), tendered vide his letter dated 20 March 2026, from the position of Chief Executive Officer and Managing Director of the Company w.e.f. close of business hours of 31 March 2026 to transit into another leadership role within the Biocon Group. Powered by Capital Market - Live News

Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda�). Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption. Powered by Capital Market - Live News

Net profit of Biocon rose 472.91% to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4123.00 crore in the quarter ended December 2025 as against Rs 3773.00 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales4123.003773.00 9 OPM %20.2219.93 - PBDT740.90563.20 32 PBT225.60137.80 64 NP143.8025.10 473 Powered by Capital Market - Live News